Anti-PDZ and LIM domain-1 (PDLIM1) AAbs were able to differentiate both ovarian cancer patients from healthy controls (AUC 0.76) and ovarian benign tumors (AUC 0.76), as well as to identify 41% of early-stage and 39% of late-stage ovarian cancer, respectively. Here, PDLIM1 is linked to ovarian benign neoplasm.